Lacerta Therapeutics Expands Executive Leadership Team
UF startup Lacerta Therapeutics, a preclinical-stage gene therapy company, announces an expansion in the executive leadership team: illustrating Lacerta’s commitment to developing a constellation of gene-based therapies.
RTI Surgical: Plant Director’s Passion and Engagement Inspires Team
A passion to find a position with a company that directly impacts people's lives led Catisha Turner to join UF startup RTI Surgical, after serving in the United States Navy for six years.
Capri EGM Build-to-Suit Program Acquires Life Science Real Estate Asset for Company Manufacturing Antibodies for Department of Defense and mRNA for COVID-19 Vaccine
UF startup Ology Bioservices, a wholly owned subsidiary of Resilience, and the operator of the Lab & Research facility, has recently been awarded contract valued as much as $250 million by the Department of Defense for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT).
GrowFL Announces Lacerta Therapeutics as an Honoree: 11th Annual Florida Companies to Watch
Lacerta Therapeutics is pleased to be among the top 50 second-stage companies in Florida selected as an 11th Annual GrowFL Florida Companies to Watch honoree, a statewide competition that identifies companies expected to see significant growth over the next several years.
National Resilience Snares Takeda Plasma Development and Manufacturing Deal
Resilience has clinched a deal to chip in on development and manufacturing of “multiple” products in Takeda’s plasma-derived therapies portfolio.
Resilience Subsidiary Ology Bioservices Awarded Contract Worth Up To $250 Million from U.S. Department of Defense for Botulinum Neurotoxin Treatment
The U.S. Department of Defense (DOD) has awarded UF startup Ology Bioservices, Inc. (Ology), a wholly-owned subsidiary of Resilience, a contract valued as much as $250 million for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT).
Mobile Eye Care Clinic Offering Free Exams, Glasses to Boston Students
Many people have put off medical care during the pandemic and that includes eye exams for children. But on Tuesday, the doctor -- funded by UF startup AGTC -- went to the students at one Boston school.
Sharks: From Mortal Foes to Medical Inspiration
UF researcher Anthony Brennan's discovery that the pattern of sharkskin prevents bacteria from adhering has led to the development of company Sharklet's Foley catheter and wound dressing.
AGTC-501 Gene Therapy Offers Vision Gains for X-Linked RP
AGTC-501 (Applied Genetic Technologies Corporation), a novel gene therapy in development for the potential treatment of X-linked retinitis pigmentosa (RP), showed an acceptable safety profile and visual function improvements when administered in the study’s higher dose groups, according to Robert A. Sisk, MD, FACS, from the Cincinnati Eye Institute in Ohio.
Surgalign Receives FDA Clearance for Surgical Guidance System
Surgalign Holdings Inc. said Tuesday it has received initial U.S. Food & Drug Administration clearance for its HOLO Portal surgical guidance system for use within lumbar spine procedures.
